SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,589,443 with 63,351,197,653 in circulation. The last known price of XRP is 1.24455819 USD and is down -0.63 over the last 24 hours. It is currently trading on 1893 active market(s) with $917,900,293.08 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff linked by traders to the Binance hack, while Ripples Swell announcements have drawn disappointment over the tokens muted response. The main debate is whether Ripples partnerships, bank charter and RLUSD growth will create demand for XRP, or primarily benefit Ripple and its stablecoin instead.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is dominated by the midterm elections and Trumps political fortunes, with traders debating how the outcome could affect DJT and broader markets; speculation over Iran-war escalation and oil prices adds to the uncertainty. Sentiment is mostly bearish, with posts citing DJTs sharp decline and weak fundamentals, though some traders anticipate a rebound.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026...

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline

Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. (Syndax or the Company) (NASDAQ: SNDX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)PR NewswireNEW YORK, Oct. 13, 2026SNDX shareholders saw the market open to losses of more than...

Syndax Pharmaceuticals Suffers Pipeline Blow

Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.read more...

Nasdaq Futures Slide As AI "Casino" Hangover Crushes Kospi; S&P Flat After JPM FICC Miss

Nasdaq Futures Slide As AI "Casino" Hangover Crushes Kospi; S&P Flat After JPM FICC Miss

 US futures are mixed with the Nasdaq lagging as the AI rout that started on Wall Street on Monday ricocheted through Asia, where the Kospi crashed as much as 7% after Broadcom's Hock Tan likened AI...

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.read more...

Syndax Reports Phase 2 Setback For Axatilimab In Idiopathic Pulmonary Fibrosis

(RTTNews) - Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate of decline in forced vital capacity (FVC...

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?  

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The trial result ends Syndax’s plans to advance the drug further in idiopathic pulmonary fibrosis.</li><li>The company said the results do not affect ongoing trials of the same drug in other settings.</li><li>Axatilimab is already approved and sold as Niktimvo for chronic graft-versus-host disease, a serious complication that can follow stem-cell transplants.</li></ul><p>Syndax Pharmaceuticals (SNDX) shares tumbled 15% after hours on Monday after the company said its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis, a progressive and often fatal lung-scarring disease.</p><h2 class="st-heading-2">SNDX’s Trial Falls Short Of Key Lung Function Goal</h2><p>The 26-week MAXPIRe study enrolled about 145 patients across 62 sites in 14 countries. Participants were randomly assigned to receive axatilimab or placebo every two weeks, on top of any standard antifibrotic drugs they were already taking. The primary measure was the annualized rate of decline in forced vital capacity—essentially how quickly patients were losing the ability to push air out of their lungs.</p><p>Axatilimab did not slow that decline better than placebo. Secondary measures, including time to disease progression and quality-of-life scores, were also reported without evidence of benefit. The result ends Syndax’s plans to advance the drug further in idiopathic pulmonary fibrosis.</p><h2 class="st-heading-2">Drug Proves Safe But Company Drops IPF Plans</h2><p>Safety data looked relatively clean. Side effects leading to treatment discontinuation were low and similar between the drug and placebo arms, and no new safety concerns emerged. There were no treatment-related deaths. The most common side effects matched those seen in earlier studies of the medicine.</p><p>“The MAXPIRe trial did not meet its primary endpoint, and we are disappointed by this outcome given the promising scientific rationale in IPF,” said Nick Botwood, Syndax’s head of research and development and chief medical officer. The company said the results do not affect ongoing trials of the same drug in other settings.</p><h2 class="st-heading-2">Syndax Focus Shifts To Existing Blood Disorder Franchise</h2><p>Axatilimab is already approved and sold as Niktimvo for chronic graft-versus-host disease, a serious complication that can follow stem-cell transplants. Syndax and partner Incyte are testing it in combination regimens for newly diagnosed patients in that indication, with data expected later this year and in early 2028. Chief Executive Michael Metzger said the company remains focused on pushing both axatilimab and its other commercial drug, revumenib, into earlier lines of treatment.</p><p>Syndax’s announcement comes on the heels of Bristol Myers Squibb announcing mixed results from its late-stage IPF trial. The company said earlier on Monday that patients receiving a 60 mg twice-daily dose of admilparant showed statistically significant improvement in lung function, while those on the higher 120 mg twice-daily dose did not.</p><h2 class="st-heading-2">How Did SNDX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around SNDX stayed within neutral territory over the past 2 months, while message volume rose from normal to high levels.</p><p>A Stocktwits user said they bought more shares on the dip, highlighting that the drug has more data due this quarter and is already approved for other indications.</p><p><stembedurl>https://stocktwits.com/BioRich/message/666322476</stembedurl></p><p><a class="mention" data-mention="$SNDX" data-symbol-id="SNDX" href="https://stocktwits.com/symbol/SNDX" target="_blank">SNDX stock</a> fell by 21% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/chamath-palihapitiya-elon-musk-highlight-power-cooling-as-real-barriers-in-the-ai-race-where-everyone-competes-with-everyone/cZxINw3RB8F">Chamath Palihapitiya, Elon Musk Highlight Power, Cooling As Real Barriers In The AI Race Where ‘Everyone Competes With Everyone’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis. 

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis. 


Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.65
Prev Close	$14.15
Open	$14.06
Dividend Yield	0.00%
50-Day Moving Average	$17.18
Beta	1.16
Avg. Volume	1.83M
PE Ratio	-5.42

52-Week High	$25.59
52-Week Low	$12.80
Market Capitalization	$1.22B
EPS (Annual)	-$3.29
Price to Book	80.59
Revenue Per Employee	$578,362.42

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNDX Fundamentals